Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 8/20 | 0.58 |
| ▸ | JUN | P05412 | 7/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 7/20 | 0.58 |
| ▸ | RELA | Q04206 | 7/20 | 0.58 |
| ▸ | FOS | P01100 | 5/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ATF1 | P18846 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30574458 | 1.00 | NFKB1 (0.58) | NFKB1JUNNFKB2RELAFOS | |
| SCHEMBL573798 | 0.87 | ALDH1A1 (0.54) | NFKB1JUNNFKB2RELAFOS | |
| SCHEMBL423492 | 0.85 | JUN (0.60) | NFKB1JUNNFKB2RELAFOS | |
| SCHEMBL4425453 | 0.84 | JUN (0.59) | NFKB1JUNNFKB2RELAFOS | |
| SCHEMBL8543216 | 0.84 | KDM4E (0.72) | NFKB1JUNNFKB2RELAFOS | |
| SCHEMBL28874828 | 0.84 | MAPT (0.44) | NFKB1JUNNFKB2RELAFOS | |
| SCHEMBL3283794 | 0.83 | JUN (0.58) | NFKB1JUNNFKB2RELAFOS | |
| SCHEMBL17393706 | 0.83 | JUN (0.58) | NFKB1JUNNFKB2RELAFOS | |
| SCHEMBL12844275 | 0.83 | JUN (0.58) | NFKB1JUNNFKB2RELAFOS | |
| SCHEMBL12775469 | 0.82 | KDM4E (0.61) | NFKB1JUNNFKB2RELAFOS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 245 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441690-B2 | Benzamide derivative compound, method for preparing same, and pharmaceutical composition for treating or preventing inflammatory disease containing same as active ingredient | Seoul National University R&DBFoundation (KR) | 2025-10-14 | — | — | US | disclosed |
| US-20250223280-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2025-07-10 | — | — | US | disclosed |
| US-20250188040-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS INC | 2025-06-12 | — | — | US | disclosed |
| US-12312340-B2 | Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins | AVILAR THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| EP-4551555-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | Vividion Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| WO-2025087763-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS HERBICIDES | SYNGENTA CROP PROTECTION AG (CH) | 2025-05-01 | — | — | WO | disclosed |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-12187685-B2 | Pharmaceutical compositions comprising WRN helicase inhibitors | VIVIDION THERAPEUTICS, INC. | 2025-01-07 | — | — | US | disclosed |
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | ENANTA PHARM INC (US) | 2024-10-31 | — | — | US | disclosed |
| EP-1175408-A1 | PYRIMIDINONE COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 2002-01-30 | — | — | EP | disclosed |
| EP-1173424-A1 | PYRIMIDINE COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000066567-A1 | PYRIMIDINONE COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 2000-11-09 | — | — | WO | disclosed |
| WO-2000066566-A1 | PYRIMIDINE COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 2000-11-09 | — | — | WO | disclosed |
| US-5935966-A | COMPOUNDS THAT BLOCK THE ACTIVATION OF TRANSCRIPTION FACTORS THROUGH INHIBITION OF A FAMILY OF SPECIFIC KINASES, DECREASING PROINFLAMMATORY PROTEINS TO TREAT AUTOIMMUNE DISEASES AND AS GENERAL ANTIINFLAMMATORY AGENTS | SIGNAL PHARMACEUTICALS, INC. (US) | 1999-08-10 | — | — | US | disclosed |
| US-5852028-A | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions | SIGNAL PHARMACEUTICALS, INC. (US) | 1998-12-22 | — | — | US | disclosed |
| WO-1998038171-A1 | PYRIMIDINE CARBOXYLATES AND RELATED COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS | SIGNAL PHARMACEUTICALS, INC. (US) | 1998-09-03 | — | — | WO | disclosed |
| WO-1997009325-A1 | PYRIMIDINE CARBOXYLATES AND RELATED COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS | SIGNAL PHARMACEUTICALS, INC. (US) | 1997-03-13 | — | — | WO | disclosed |
| US-5250548-A | Treating hypertension, heart failure | ABBOTT LABORATORIES (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0475206-A2 | Angiotensin II receptor antagonists | ABBOTT LABORATORIES (US) | 1992-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12312340-B2 | Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins | ASGR1, FCGR2A, FCGR3B | NFKB1 3276/4885JUN 3286/4885NFKB2 3018/4885 |
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | GABRA5, GABRA1, GABBR2 | NFKB1 1886/4885JUN 3850/4885NFKB2 2442/4885 |
| US-20250223280-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | ASGR1, FCGR2A, FCGR3B | NFKB1 3276/4885JUN 3286/4885NFKB2 3018/4885 |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | NFKB1 1886/4885JUN 3850/4885NFKB2 2442/4885 |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ACE, ACE2, SPCS3 | NFKB1 1029/4885JUN 4226/4885NFKB2 1356/4885 |
| US-12187685-B2 | Pharmaceutical compositions comprising WRN helicase inhibitors | RECQL, BLM, WRN | NFKB1 1367/4885JUN 4357/4885NFKB2 1476/4885 |
| US-20250188040-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | RECQL, BLM, WRN | NFKB1 1367/4885JUN 4357/4885NFKB2 1476/4885 |
| US-12441690-B2 | Benzamide derivative compound, method for preparing same, and pharmaceutical composition for treating or preventing inflammatory disease containing same as active ingredient | IL4, IL5, IL15 | NFKB1 164/4885JUN 3952/4885NFKB2 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.